Substance / Medication

Calcium acetate

Overview

Active Ingredient
calcium acetate
RxNorm CUI
214342

Indications

Calcium acetate capsules are a phosphate binder indicated to reduce serum phosphorus in patients with end stage renal disease (ESRD).

Labeler: Westminster Pharmaceuticals, LLCUpdated: 2026-02-24T00:00:00.000ZFull label on DailyMed

Contraindications

When this intervention should not be used

Patients with hypercalcemia.

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Detailed dosage and administration information is available in the full FDA drug label.

View full prescribing information on DailyMed

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Clinical Trials

6 trials linked to this intervention

6
Total Trials
1
Recruiting
2
With Results

Research Evidence

Published studies and systematic reviews

Sort:
Comparison of calcium acetate and sevelamer on vascular function and fibroblast growth factor 23 in CKD patients: a randomized clinical trial.
Yilmaz Mahmut Ilker, Sonmez Alper, Saglam Mutlu et al. · Am J Kidney Dis · 2012
PMID: 22137672RCT
A comparison of sevelamer hydrochloride with calcium acetate on biomarkers of bone turnover in hemodialysis patients.
Liu Yao-Lung, Lin Hsin-Hung, Yu Chun-Chen et al. · Ren Fail · 2006
PMID: 17162430RCT
Gut microbiome in hemodialysis patients treated with calcium acetate or treated with sucroferric oxyhydroxide: a pilot study.
Merino-Ribas Ana, Araujo Ricardo, Bancu Ioana et al. · Int Urol Nephrol · 2022
PMID: 34923600TrialFull text (PMC)
Effect of the Phosphate Binders Sevelamer Carbonate and Calcium Acetate on the Pharmacokinetics of Roxadustat After Concomitant or Time-separated Administration in Healthy Individuals.
Groenendaal-van de Meent Dorien, Kerbusch Virginie, Barroso-Fernandez Begona et al. · Clin Ther · 2021
PMID: 33962762Trial
Treatment of hyperphosphatemia in hemodialysis patients: The Calcium Acetate Renagel Evaluation (CARE Study).
Qunibi Wajeh Y, Hootkins Robert E, McDowell Laveta L et al. · Kidney Int · 2004
PMID: 15086935Trial
Treatment of hyperphosphatemia with sevelamer hydrochloride in hemodialysis patients: a comparison with calcium acetate.
Hervás José G, Prados Dolores, Cerezo Sebastián · Kidney Int Suppl · 2003
PMID: 12753270Trial
Effects of sevelamer hydrochloride and calcium acetate on the oral bioavailability of ciprofloxacin.
Kays Michael B, Overholser Brian R, Mueller Bruce A et al. · Am J Kidney Dis · 2003
PMID: 14655198Trial
A preference study: calcium acetate tablets versus gelcaps in hemodialysis patients.
Kaplan Mark R, Stashenko Cindy L, Bledsoe Andra L et al. · Nephrol Nurs J · 2002
PMID: 12224369Trial
Calcium acetate versus calcium carbonate in the control of hyperphosphatemia in hemodialysis patients.
d'Almeida Filho E J, da Cruz E A, Hoette M et al. · Sao Paulo Med J · 2000
PMID: 11120549TrialFull text (PMC)

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Adverse reaction and safety data for this drug is sourced from the FDA-approved label.

View adverse reactions & drug interactions on DailyMed

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Calcium acetate (substance)
SNOMED CT
387019008
UMLS CUI
C0717537
RxNorm CUI
214342
Labeler
Westminster Pharmaceuticals, LLC

Clinical Data

This intervention maps to 5 entities in the Ltrl knowledge graph.

5
Conditions
0
Biomarkers
0
Specialists
0
Symptoms
6
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.